A new 4-phenyl-1,8-naphthyridine derivative affects carcinoma cell proliferation by impairing cell cycle progression and inducing apoptosis

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 6, 2012, Pages 653-662

  Capozzi, Antonella ^a   Mantuano, Elisabetta ^a   Matarrese, Paola ^b   Saccomanni, Giuseppe ^c   Manera, Clementina ^c   Mattei, Vincenzo ^a   Gambardella, Lucrezia ^b   Malorni, Walter ^b,d   Sorice, Maurizio ^a   Misasi, Roberta ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d Istituto San Raffaele   (Italy)

Author keywords

Annexin V; Apoptosis; Bromodeoxyuridine; Cancer; Cell cycle; Cytotoxicity; Hep 2 cells; JC 1; Microtubules; Mitochondria; Mitochondrial Membrane Potential; Naphthyridine derivative; Propidium iodide; Topoisomerase II; Tubulin

Indexed keywords

4 PHENYL 1,8 NAPHTHYRIDINE DERIVATIVE; 4 PHENYL 2,7 DI(PIPERAZIN 1 YL) 1,8 NAPHTHYRIDINE; ANTINEOPLASTIC AGENT; DEMECOLCINE; DNA TOPOISOMERASE (ATP HYDROLYSING); NAPHTHYRIDINE DERIVATIVE; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; IC 50; LARYNX CARCINOMA; MITOCHONDRION; MITOSIS SPINDLE;

EID: 84861680273     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012800617731     Document Type: Article

References (35)

1. Gonzalez-Nicolini, V.; Fussenegger, M., In vitro assays for anticancer drug discovery--a novel approach based on engineered mammalian cell lines. Anti-cancer drugs 2005, 16 (3), 223-8.
2. Benson, J. D.; Chen, Y. N.; Cornell-Kennon, S. A.; Dorsch, M.; Kim, S.; Leszczyniecka, M.; Sellers, W. R.; Lengauer, C., Validating cancer drug targets. Nature 2006, 441 (7092), 451-6.
3. Jordan, M. A., Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Current medicinal chemistry. Anticancer agents 2002, 2 (1), 1-17.
4. Lee, F. Y.; Borzilleri, R.; Fairchild, C. R.; Kamath, A.; Smykla, R.; Kramer, R.; Vite, G., Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer chemotherapy and pharmacology 2008, 63 (1), 157-166.
5. Desai, A.; Mitchison, T. J., Microtubule polymerization dynamics. Annual review of cell and developmental biology 1997, 13, 83-117.
6. Nogales, E.; Wolf, S. G.; Downing, K. H., Structure of the alpha beta tubulin dimer by electron crystallography. Nature 1998, 391 (6663), 199-203.
7. Rowinsky, E. K.; Calvo, E., Novel agents that target tublin and related elements. Seminars in oncology 2006, 33 (4), 421-35.
8. Rai, S. S.; Wolff, J., Localization of the vinblastine-binding site on beta-tubulin. The Journal of biological chemistry 1996, 271 (25), 14707-11.
9. Tanaka, Y.; Fujiwara, K.; Tanaka, H.; Maehata, K.; Kohno, I., Paclitaxel inhibits expression of heat shock protein 27 in ovarian and uterine cancer cells. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society 2004, 14 (4), 616-20.
10. Smith, J. A.; Jordan, M. A., Determination of drug binding to microtubules in vitro. Methods in cell biology 2010, 95, 289-99.
11. Azema, J.; Guidetti, B.; Dewelle, J.; Le Calve, B.; Mijatovic, T.; Korolyov, A.; Vaysse, J.; Malet-Martino, M.; Martino, R.; Kiss, R., 7-(4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents. Bioorganic & medicinal chemistry 2009, 17 (15), 5396-407.
12. You, Q. D.; Li, Z. Y.; Huang, C. H.; Yang, Q.; Wang, X. J.; Guo, Q. L.; Chen, X. G.; He, X. G.; Li, T. K.; Chern, J. W., Discovery of a novel series of quinolone and naphthyridine derivatives as potential topoisomerase I inhibitors by scaffold modification. Journal of medicinal chemistry 2009, 52 (18), 5649-61.
13. Ohemeng, K. A.; Podlogar, B. L.; Nguyen, V. N.; Bernstein, J. I.; Krause, H. M.; Hilliard, J. J.; Barrett, J. F., DNA gyrase inhibitory and antimicrobial activities of some diphenic acid monohydroxamides. Journal of medicinal chemistry 1997, 40 (20), 3292-6.
14. Shen, L. L.; Mitscher, L. A.; Sharma, P. N.; O'Donnell, T. J.; Chu, D. W.; Cooper, C. S.; Rosen, T.; Pernet, A. G., Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. Biochemistry 1989, 28 (9), 3886-94.
15. Gasparotto, V.; Castagliuolo, I.; Ferlin, M. G., 3-substituted 7-phenyl-pyrroloquinolinones show potent cytotoxic activity in human cancer cell lines. Journal of medicinal chemistry 2007, 50 (22), 5509-13.
16. Ferrarini, P. L.; Manera, C.; Mori, C.; Badawneh, M.; Saccomanni, G., Synthesis and evaluation of antimycobacterial activity of 4-phenyl-1,8-naphthyridine derivatives. Farmaco 1998, 53 (12), 741-6.
17. Brachman, D. G.; Beckett, M.; Graves, D.; Haraf, D.; Vokes, E.; Weichselbaum, R. R., p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer research 1993, 53 (16), 3667-9.
18. Douros, J.; Suffness, M., New natural products of interest under development at the National Cancer Institute. Cancer chemotherapy and pharmacology 1978, 1 (2), 91-100.
19. Wilson, A. P., Citotoxicity and viability assays. In Animal cell culture: a practical approach, Freshney, R. I., Ed. Oxford University Press, 1992; pp 263-303.
20. Nourbakhsh, M.; Kalble, S.; Dorrie, A.; Hauser, H.; Resch, K.; Kracht, M., The NF-kappa b repressing factor is involved in basal repression and interleukin (IL)-1-induced activation of IL-8 transcription by binding to a conserved NF-kappa b-flanking sequence element. The Journal of biological chemistry 2001, 276 (6), 4501-8.
21. Vannucchi, S.; Percario, Z. A.; Chiantore, M. V.; Matarrese, P.; Chelbi-Alix, M. K.; Fagioli, M.; Pelicci, P. G.; Malorni, W.; Fiorucci, G.; Romeo, G.; Affabris, E., Interferon-beta induces S phase slowing via up-regulated expression of PML in squamous carcinoma cells. Oncogene 2000, 19 (44), 5041-53.
22. Kroemer, G.; Galluzzi, L.; Brenner, C., Mitochondrial membrane permeabilization in cell death. Physiological reviews 2007, 87 (1), 99-163.
23. Liu, L. F., DNA topoisomerase poisons as antitumor drugs. Annual review of biochemistry 1989, 58, 351-75.
24. Luo, K.; Yuan, J.; Chen, J.; Lou, Z., Topoisomerase IIalpha controls the decatenation checkpoint. Nature cell biology 2009, 11 (2), 204-10.
25. Diamond, L.; Gelboin, H. V., Alpha-naphthoflavone: an inhibitor of hydrocarbon cytotoxicity and microsomal hydroxylase. Science 1969, 166 (908), 1023-5.
26. Rowinsky, E. K.; Burke, P. J.; Karp, J. E.; Tucker, R. W.; Ettinger, D. S.; Donehower, R. C., Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer research 1989, 49 (16), 4640-7.
27. Speicher, L. A.; Barone, L.; Tew, K. D., Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer research 1992, 52 (16), 4433-40.
28. Rowinsky, E. K.; Donehower, R. C., Paclitaxel (taxol). The New England journal of medicine 1995, 332 (15), 1004-14.
29. Jordan, M. A.; Himes, R. H.; Wilson, L., Comparison of the effects of vinblastine, vincristine, vindesine, and vinepidine on microtubule dynamics and cell proliferation in vitro. Cancer research 1985, 45 (6), 2741-7.
30. Yoo, Y. D.; Park, J. K.; Choi, J. Y.; Lee, K. H.; Kang, Y. K.; Kim, C. S.; Shin, S. W.; Kim, Y. H.; Kim, J. S., CDK4 down-regulation induced by paclitaxel is associated with G1 arrest in gastric cancer cells. Clinical cancer research: an official journal of the American Association for Cancer Research 1998, 4 (12), 3063-8.
31. Mullan, P. B.; Quinn, J. E.; Gilmore, P. M.; McWilliams, S.; Andrews, H.; Gervin, C.; McCabe, N.; McKenna, S.; White, P.; Song, Y. H.; Maheswaran, S.; Liu, E.; Haber, D. A.; Johnston, P. G.; Harkin, D. P., BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agents. Oncogene 2001, 20 (43), 6123-31.
32. Sarkar, F. H.; Li, Y., Markers of apoptosis. Methods in molecular medicine 2006, 120, 147-60.
33. Pettersson, F.; Colston, K. W.; Dalgleish, A. G., Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro. British journal of cancer 2000, 83 (2), 239-45.
34. Viola, G.; Cecconet, L.; Leszl, A.; Basso, G.; Brun, P.; Salvador, A.; Dall'Acqua, F.; Diana, P.; Barraja, P.; Cirrincione, G., Pyrrolotetrazinones deazaanalogues of temozolomide induce apoptosis in Jurkat cell line: involvement of tubulin polymerization inhibition. Cancer chemotherapy and pharmacology 2009, 64 (6), 1235-51.
35. Aissat, N.; Le Tourneau, C.; Ghoul, A.; Serova, M.; Bieche, I.; Lokiec, F.; Raymond, E.; Faivre, S., Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer chemotherapy and pharmacology 2008, 62 (2), 305-13.